Human monocarboxylate transporter 1 antibodies and uses thereof
Anti-human MCT1 antibodies with specific VH and VL sequences address the challenge of off-target toxicities from small molecule inhibitors by selectively binding and inhibiting MCT1, providing effective treatment for autoimmune disorders and other conditions with enhanced safety and manufacturing profiles.
Patent Information
- Authority / Receiving Office
- AU · AU
- Patent Type
- Applications
- Current Assignee / Owner
- IMMUNOMETABOLISM DEVELOPMENT COMPANY LLC
- Filing Date
- 2022-09-14
- Publication Date
- 2026-07-23
AI Technical Summary
Current therapies targeting human monocarboxylate transporter 1 (MCT1) face challenges due to off-target toxicities from small molecule inhibitors, and there is a need for antibodies that selectively and specifically bind human MCT1 for therapeutic use, particularly in treating autoimmune conditions and other disorders.
Development of antibodies, such as anti-human MCT1 antibodies with specific VH and VL sequences, which selectively bind to human MCT1, inhibiting its functions and having desirable developability and patient safety profiles, including low immunogenicity and minimal off-target effects.
The anti-human MCT1 antibodies effectively inhibit MCT1-mediated responses, treat MCT1-associated disorders like autoimmune diseases, and promote regulatory T cell differentiation, with improved safety and manufacturing profiles.
Smart Images
Figure 00000111_0000 
Figure 00000112_0000 
Figure 00000113_0000